Valo Health and nference Announce Long-term Partnership to Accelerate Human-Centric Drug Discovery and Development

CAM­BRIDGE, Mass. & LEX­ING­TON, Mass., US, 18 March 2025--(BUSI­NESS WIRE)–Valo Health, Inc. (“Valo”), a biotech­nol­o­gy com­pa­ny focused on trans­form­ing the drug dis­cov­ery and devel­op­ment process using human-cen­tric data and arti­fi­cial intel­li­gence (AI), today announced a mul­ti-year col­lab­o­ra­tion with nfer­ence, a com­pa­ny ded­i­cat­ed to trans­form­ing health­care by mak­ing bio­med­ical knowl­edge com­putable. The research col­lab­o­ra­tion will lever­age decades of com­pre­hen­sive, HIPAA-com­pli­ant, ful­ly de-iden­ti­fied patient-lev­el data from the nfer­ence fed­er­at­ed AI net­work to enhance the capa­bil­i­ties of Valo’s Opal Com­pu­ta­tion­al Plat­form™, enabling advances in the dis­cov­ery and devel­op­ment of drug tar­gets and pre­ci­sion medicines.

“We are enter­ing a new era of med­i­cine made pos­si­ble by abun­dant clin­i­cal data and an enhanced abil­i­ty to ana­lyze it,” said Brett Black­man, Ph.D., chief oper­at­ing offi­cer at Valo Health. ​“Our col­lab­o­ra­tion gives us access to nfer­ence’s deep mul­ti­modal, lon­gi­tu­di­nal data and AI soft­ware plat­form, which will allow us to learn through obser­va­tion while accel­er­at­ing and widen­ing the scope of exper­i­men­ta­tion. Togeth­er, with nfer­ence and our oth­er ecosys­tem part­ners, we aim to short­en the drug devel­op­ment time­line and bring crit­i­cal treat­ment options to the patients who need them the most.”

The col­lab­o­ra­tion grants Valo the abil­i­ty to use the nfer­ence AI plat­form, the industry’s most com­pre­hen­sive mul­ti­modal bio­med­ical knowl­edge base, incor­po­rat­ing deep, de-iden­ti­fied insights from top-ranked aca­d­e­m­ic med­ical cen­ters that are part of the nfer­ence fed­er­at­ed AI net­work. Use of the nfer­ence AI plat­form pro­vides Valo with real-time access to a wide range of data modes, includ­ing insights from physi­cians’ notes, med­ical imag­ing and out­comes data, patients’ diag­nos­tic and treat­ment infor­ma­tion, and lab results.

The partnership’s unique col­lab­o­ra­tion mod­el sup­ports Valo’s nov­el, human-cen­tric approach­es to tar­get dis­cov­ery, clin­i­cal trans­la­tion, and bio­mark­er dis­cov­ery. As nfer­ence brings onboard addi­tion­al data modal­i­ties, Valo will have access to an expand­ing pool of rich data and advanced ana­lyt­ics tools that will yield deep­er insights to sup­port its trans­la­tion­al research programs.

“Our part­ner­ship with Valo demon­strates how the nfer­ence Agen­tic AI plat­form can deliv­er clin­i­cal knowl­edge and de-iden­ti­fied, real-world patient insights to accel­er­ate drug dis­cov­ery and devel­op­ment,” said Venky Soundarara­jan, Ph.D., co-founder and chief sci­en­tif­ic offi­cer at nfer­ence. ​“In com­bi­na­tion with Valo’s dig­i­tal-native drug dis­cov­ery process and human-cen­tric data plat­form, our col­lab­o­ra­tion will expe­dite bio­med­ical dis­cov­ery for those patient pop­u­la­tions who have the most unmet clin­i­cal needs.”

About Valo Health
Valo Health, Inc. is lever­ag­ing arti­fi­cial intel­li­gence (AI) and advanced ana­lyt­ics to bet­ter learn from the patient expe­ri­ence to dis­cov­er and devel­op bet­ter med­i­cines at greater speed and scale. The company’s Opal Plat­form™ is a human-cen­tric, AI-dri­ven drug devel­op­ment engine that uses AI to iden­ti­fy and val­i­date nov­el drug tar­gets, using real-world data and human mod­els to rapid­ly dis­cov­er and devel­op small mol­e­cule ther­a­pies against those tar­gets with more pre­dictable safe­ty and effi­ca­cy. Found­ed by Flag­ship Pio­neer­ing and head­quar­tered in Lex­ing­ton, Mass., Valo also has offices in New York, N.Y. and Tel Aviv, Israel. To learn more, vis­it valo​health​.com.

About nfer­ence
nfer­ence is unlock­ing the poten­tial of health­care data with AI, deliv­er­ing real-world evi­dence, insights, and solu­tions informed by the most com­pre­hen­sive mul­ti­modal data across all ther­a­peu­tic areas. Our exten­sive de-iden­ti­fied, lon­gi­tu­di­nal data includes decades of clin­i­cal notes along with rich patient his­to­ries, vitals, lab tests, radi­ol­o­gy images, dig­i­tal pathol­o­gy, genomics, and elec­tro­phys­i­ol­o­gy wave­forms. Our fed­er­at­ed data plat­form, com­prised of pre­mier health­care orga­ni­za­tions, enables advanced research and cus­tom AI mod­el devel­op­ment. With unprece­dent­ed access to data from over 40 mil­lion patient jour­neys, our part­ners can tar­get dis­cov­ery, accel­er­ate clin­i­cal tri­al design, and opti­mize life­cy­cle man­age­ment. Fol­low nfer­ence on LinkedIn. Vis­it us at www​.nfer​ence​.com.
 

Media Con­tacts
Valo Health:
Corey Carmichael
(862) 260‑7929
corey.​carmichael@​smithsolve.​com

nfer­ence:
Matthew Hurchik
mhurchik@​nference.​net